These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 36725399)
1. The efficacy and safety of tacrolimus in patients with dermatomyositis/polymyositis: A meta-analysis and systematic review. Liao J; Peng X; Liu J; Xie X; Wang J Eur J Intern Med; 2023 Apr; 110():35-40. PubMed ID: 36725399 [TBL] [Abstract][Full Text] [Related]
2. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Ge Y; Zhou H; Shi J; Ye B; Peng Q; Lu X; Wang G Clin Rheumatol; 2015 Dec; 34(12):2097-103. PubMed ID: 26328518 [TBL] [Abstract][Full Text] [Related]
3. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Yokoyama Y; Furuta S; Ikeda K; Hirose K; Nakajima H Mod Rheumatol; 2015; 25(6):888-92. PubMed ID: 25775144 [TBL] [Abstract][Full Text] [Related]
4. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Takada K; Katada Y; Ito S; Hayashi T; Kishi J; Itoh K; Yamashita H; Hirakata M; Kawahata K; Kawakami A; Watanabe N; Atsumi T; Takasaki Y; Miyasaka N Rheumatology (Oxford); 2020 May; 59(5):1084-1093. PubMed ID: 31539061 [TBL] [Abstract][Full Text] [Related]
5. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study. Shimojima Y; Ishii W; Matsuda M; Tazawa K; Ikeda S BMC Musculoskelet Disord; 2012 Nov; 13():228. PubMed ID: 23173570 [TBL] [Abstract][Full Text] [Related]
6. Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan. Kuwana M; Wakasugi N; Furuya T; Uno S; Suda T J Rheumatol; 2022 Jul; 49(7):707-718. PubMed ID: 35428708 [TBL] [Abstract][Full Text] [Related]
7. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Matsubara S; Kondo K; Sugaya K; Miyamoto K Clin Rheumatol; 2012 Oct; 31(10):1493-8. PubMed ID: 22886003 [TBL] [Abstract][Full Text] [Related]
8. The therapeutic efficacy and safety of intravenous immunoglobulin in dermatomyositis and polymyositis: A systematic review and meta-analysis. Xiong A; Qiang Y; Cao Y; Shuai Y; Chen H; Xiang Q; Hu Z; Song Z; Zhou S; Zhang Y; Cui H; Wang Y; Luo J; Shuai S; Yang Y Mod Rheumatol; 2023 Apr; 33(3):533-542. PubMed ID: 35660927 [TBL] [Abstract][Full Text] [Related]
9. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Ueno KI; Shimojima Y; Kishida D; Sekijima Y; Ikeda SI Int J Rheum Dis; 2016 Dec; 19(12):1322-1330. PubMed ID: 27457756 [TBL] [Abstract][Full Text] [Related]
10. Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. Raouf J; Idborg H; Englund P; Alexanderson H; Dastmalchi M; Jakobsson PJ; Lundberg IE; Korotkova M Arthritis Res Ther; 2018 May; 20(1):83. PubMed ID: 29720222 [TBL] [Abstract][Full Text] [Related]
11. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Kurita T; Yasuda S; Oba K; Odani T; Kono M; Otomo K; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Atsumi T Rheumatology (Oxford); 2015 Jan; 54(1):39-44. PubMed ID: 24764266 [TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Unger L; Kampf S; Lüthke K; Aringer M Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995 [TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory polymyositis and dermatomyositis. Ytterberg SR Curr Rheumatol Rep; 2006 Jun; 8(3):167-73. PubMed ID: 16901073 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and safety of JAK inhibitors in treating polymyositis/dermatomyositis: a single-arm systemic meta-analysis. Ma C; Liu M; Cheng Y; Wang X; Zhao Y; Wang K; Wang W Front Immunol; 2024; 15():1382728. PubMed ID: 38576610 [TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review. Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Kurita T; Yasuda S; Amengual O; Atsumi T Lupus; 2015 Jan; 24(1):3-9. PubMed ID: 25297551 [TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review. Borges IBP; Silva MG; Misse RG; Shinjo SK Rheumatol Int; 2018 Feb; 38(2):293-301. PubMed ID: 29027009 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Gordon PA; Winer JB; Hoogendijk JE; Choy EH Cochrane Database Syst Rev; 2012 Aug; 2012(8):CD003643. PubMed ID: 22895935 [TBL] [Abstract][Full Text] [Related]
19. The effects of FK506 on refractory inflammatory myopathies. Mitsui T; Kuroda Y; Ueno S; Kaji R Acta Neurol Belg; 2011 Sep; 111(3):188-94. PubMed ID: 22141281 [TBL] [Abstract][Full Text] [Related]
20. Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents. Loell I; Raouf J; Chen YW; Shi R; Nennesmo I; Alexanderson H; Dastmalchi M; Nagaraju K; Korotkova M; Lundberg IE Arthritis Res Ther; 2016 Jun; 18(1):136. PubMed ID: 27287443 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]